ASCP Corner May 7, 2019

Medical Marijuana: What Physicians Need to Know

Rajiv Radhakrishnan, MD; Mohini Ranganathan, MD; Deepak Cyril D' Souza, MD

J Clin Psychiatry 2019;80(5):18ac12537

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

As of March 2019, in the United States, “medical marijuana” has been approved in 33 states, the District of Columbia, Guam, and Puerto Rico. Marijuana, however, remains a schedule I drug per the US Drug Enforcement Administration (DEA) based on its findings that marijuana (a) has a high potential for abuse, (b) has no currently accepted medical use in treatment in the United States, and (c) lacks accepted safety for use under medical supervision. Nevertheless, today the marketplace is flooded with over 2,500 “strains” of the marijuana plant (named variously as “Mango Kush,” “Skywalker,” “Purple Haze,” “Obama Kush,” and so-called cannabidiol [CBD] strains such as “Harlequin,” “Ringo’s Gift,” “ACDC,” and “Cannatonic”) and marijuana-infused products (including edibles, concentrates, dabs, waxes, oils, and vaping fluids), each claiming unique, yet unproven, “medical” benefit.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.